YUPELRI Market Insights
"Key Factors Driving YUPELRI Growth
1. Unique once-daily nebulized LAMA positioning
YUPELRI’s biggest commercial advantage is its differentiated positioning as the only once-daily nebulized LAMA therapy for COPD in the U.S. Many moderate-to-severe COPD patients, particularly elderly patients or those with low inspiratory flow, struggle with handheld inhalers and benefit from nebulized delivery. This unique positioning gives YUPELRI a relatively protected niche within the COPD maintenance market. The FDA approval announcement highlighted that no once-daily nebulized bronchodilator option existed previously for these patients.
2. Consistent double-digit sales growth trajectory
YUPELRI has demonstrated sustained commercial momentum over recent years. According to Theravance Biopharma’s FY2024 results, U.S. net sales reached a record US$238.6 million in 2024, representing 8% year-over-year growth, while Q4 2024 sales rose 10% to US$66.7 million. In Q2 2025, sales further increased 22% year-over-year to US$66.3 million. These trends indicate continued adoption despite increasing competition in the broader COPD market.
3. Strong hospital-channel expansion
Hospital utilization has become a major growth driver for YUPELRI. Theravance reported hospital doses sold increased 31% in Q1 2024, 40% in Q3 2024, and another 31% in Q2 2025. Hospital adoption is important because COPD exacerbations frequently result in hospitalization, and nebulized therapies are often preferred in acute-care settings. Growing formulary penetration and inpatient usage may support long-term outpatient continuation after discharge.
4. Growing share within the nebulized COPD segment
YUPELRI continues gaining market share in the long-acting nebulized bronchodilator category. Theravance reported community-setting share increased to 30.5% and hospital-setting share rose to 16.6% in Q1 2024, with hospital share later approaching 19% in Q3 2024. This demonstrates strengthening physician familiarity and increasing preference for once-daily nebulized maintenance therapy.
5. Expansion opportunity in China and international markets
China represents a significant long-term opportunity because COPD is among the leading causes of mortality in the country, contributing to approximately 910,000 deaths annually. In 2023, Viatris and Theravance announced positive Phase III China data showing statistically significant improvement in trough FEV1 versus placebo. In 2025, Theravance received a US$7.5 million milestone payment from Viatris tied to China approval activities. Broader international expansion could materially increase the product’s revenue base over time.
YUPELRI Recent Developments
In June 2025, Viatris secured regulatory approval from China's NMPA for YUPELRI inhalation solution for maintenance treatment of COPD, making it the first once-daily nebulized long-acting muscarinic antagonist (LAMA) approved in China for COPD. This triggered a $7.5 million one-time payment to Theravance Biopharma, with Theravance entitled to $37.5 million in sales milestones and escalating royalties (14-20%) on Chinese net sales. Viatris handles commercialization in China.
“YUPELRI Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of YUPELRI for approved indication like Chronic obstructive pulmonary disease in the 7MM. A detailed picture of YUPELRI’s existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the YUPELRI for approved indications. The YUPELRI market report provides insights about YUPELRI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current YUPELRI performance, future market assessments inclusive of the YUPELRI market forecast analysis for approved indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of YUPELRI sales forecasts, along with factors driving its market.
YUPELRI Drug Summary
YUPELRI is a once-daily, long-acting muscarinic antagonist (LAMA) bronchodilator developed by Theravance Biopharma and Viatris for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The active ingredient, revefenacin, is administered via standard jet nebulizer, making it particularly suitable for COPD patients who have difficulty using handheld inhalers due to age, disease severity, or impaired inspiratory flow. YUPELRI works by selectively inhibiting muscarinic M3 receptors in airway smooth muscle, leading to sustained bronchodilation and improved lung function over 24 hours. Clinical studies have demonstrated significant improvements in forced expiratory volume (FEV1), favorable tolerability, and compatibility with other COPD therapies, positioning YUPELRI as an important nebulized maintenance therapy option in the COPD treatment landscape. The report provides YUPELRI’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the YUPELRI Market Report
The report provides insights into:
• A comprehensive product overview including the YUPELRI MoA, description, dosage and administration, research and development activities in approved indication like Chronic obstructive pulmonary disease.
• Elaborated details on YUPELRI regulatory milestones and other development activities have been provided in YUPELRI market report.
• The report also highlights YUPELRI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The YUPELRI market report also covers the patents information, generic entry and impact on cost cut.
• The YUPELRI market report contains current and forecasted YUPELRI sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The YUPELRI market report also features the SWOT analysis with analyst views for YUPELRI in approved indications.
Methodology
The YUPELRI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
YUPELRI Analytical Perspective by DelveInsight
• In-depth YUPELRI Market Assessment
This YUPELRI sales market forecast report provides a detailed market assessment of YUPELRI for approved indication like Chronic obstructive pulmonary disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted YUPELRI sales data uptil 2034.
• YUPELRI Clinical Assessment
The YUPELRI market report provides the clinical trials information of YUPELRI for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
YUPELRI Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
YUPELRI Market Potential & Revenue Forecast
• Projected market size for the YUPELRI and its key indications
• Estimated YUPELRI sales potential (YUPELRI peak sales forecasts)
• YUPELRI Pricing strategies and reimbursement landscape
YUPELRI Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• YUPELRI Market positioning compared to existing treatments
• YUPELRI Strengths & weaknesses relative to competitors
YUPELRI Regulatory & Commercial Milestones
• YUPELRI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
YUPELRI Clinical Differentiation
• YUPELRI Efficacy & safety advantages over existing drugs
• YUPELRI Unique selling points
YUPELRI Market Report Highlights
• In the coming years, the YUPELRI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The YUPELRI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence YUPELRI’s dominance.
• Other emerging products for Chronic obstructive pulmonary disease are expected to give tough market competition to YUPELRI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of YUPELRI in approved indications.
• Analyse YUPELRI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted YUPELRI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of YUPELRI in approved indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of YUPELRI? How strong is YUPELRI’s clinical and commercial performance?
• What is YUPELRI’s clinical trial status in each individual indications such as Chronic obstructive pulmonary disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the YUPELRI Manufacturers?
• What are the key designations that have been granted to YUPELRI for approved indications? How are they going to impact YUPELRI’s penetration in various geographies?
• What is the current and forecasted YUPELRI market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of YUPELRI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to YUPELRI for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is YUPELRI? What is the duration of therapy and what are the geographical variations in cost per patient?
